Search results
From Bioblast
- {{#ask:[[Additional label::MitoFit 2021 MgG]] {{#ask:[[Additional label::MitoFit 2021 MgG-PW]]4 KB (486 words) - 16:39, 21 January 2024
- |title=Cardoso LHD, Gnaiger E (2022) Reverse citric acid cycle and mitochondrial succinate formation under anox |year=2022-##-##2 KB (349 words) - 10:00, 26 February 2022
- |abstract=[[Gnaiger 2022 Abstract Bioblast-PB]]: The bioenergetic crosstalk between mitochondria and {{#ask:[[Additional label::MitoFit 2021.5 PB]]3 KB (414 words) - 07:25, 9 January 2024
- ...int for the mechanism. Curr Opin Struct Biol 74:102350. doi: 10.1016/j.sbi.2022.102350 {{#ask:[[Additional label::Complex I]]2 KB (214 words) - 13:43, 3 November 2023
- ...s in a wide range of FCCP concentrations from 50 to 1000ยตM. A non-invasive label-free method of hyperspectral imaging of cell autofluorescence combined with |additional=MitoFit 2022 NADH2 KB (264 words) - 17:07, 16 February 2022
- ...4 published in [https://doi.org//10.26124/bec:2022-0012 '''Bioenerg Commun 2022.12.''']'' ...k=https://www.youtube.com/watch?v=EEo3rMa_r30&t=945s|ยป''Watch the Bioblast 2022 presentation''ยซ]]6 KB (876 words) - 11:38, 12 March 2024
- {{#ask:[[Additional label::MitoFit 2021 AmR-O2]] {{Template:Cited by Komlodi 2022 MitoFit ROS review}}5 KB (700 words) - 13:33, 1 May 2024
- ::::* '''Duration''': 36 months extended additional 12 months {{#ask:[[Category:Publications]] [[Additional label::MitoKIN]]3 KB (419 words) - 18:56, 1 December 2022
- |title=Zdrazilova L, Hansikova H, Gnaiger E (2022) Comparable respiratory activity in attached and suspended human fibroblast |year=20224 KB (555 words) - 06:05, 3 April 2024
- ...evealed contractile failure at nine but not 3 weeks after ischaemia whilst label-free quantitative proteomics identified an increase in proteins promoting a {{Template:Cited by Komlodi 2022 MitoFit ROS review}}3 KB (475 words) - 21:45, 13 April 2022
- Communicated by [[Gnaiger E]] (2018-10-18) last update 2022-04-03 {{#ask:[[Additional label::Concentration]]4 KB (571 words) - 02:56, 23 January 2023
- Communicated by [[Doerrier C]] and [[Gnaiger E]] (last update 2022-07-07) :::+ The addition of non-permeabilized cells to the chambers provides additional information ([[ROUTINE]] respiration) which is not obtained in [[SUIT-001 O4 KB (557 words) - 09:53, 7 July 2022
- ::::# '''Oxidative stress''' ([[Azzi 2022 Antioxidants (Basel) |Azzi 2022]]): A prominent case of ambiguity in the grey zone between types 1 and 2 ha ::::# '''Normoxia and hypoxia''' ([[Donnelly_2022_BEC |Donnelly et al 2022]]): Anthropocentric and clinical perspectives on hypoxia clash with an evol8 KB (1,113 words) - 22:04, 3 March 2024
- Communicated by [[Gnaiger Erich]] (2018-10-18) last update 2022-08-16 {{#ask:[[Additional label::Avogadro constant]]4 KB (680 words) - 02:57, 23 January 2023
- {{#ask:[[Additional label::BEC2021.5]] Last update 2022-02-0415 KB (2,010 words) - 13:39, 1 May 2024
- {{#ask:[[Additional label::MitoFit 2021 CoQ]] |additional=Additivity, SUIT-006 Q mt D071, SUIT-006 Q ce-pce D073, SUIT-031 Q mt D072,6 KB (810 words) - 16:37, 21 January 2024
- Communicated by [[Gnaiger E |Erich Gnaiger]] (2018-09-16) last update 2022-10-26 .... {''end of Quote'': https://en.wikipedia.org/wiki/Pascal_(unit) retrieved 2022-09-28}7 KB (1,053 words) - 07:05, 6 July 2023
- ::::* '''Duration''': 24 months, extended additional 5 months ...lengths that in combination with fluorophores allow for the measurement of additional mitochondrial parameters, such as membrane potential, H<sub>2</sub>O<sub>2<14 KB (1,813 words) - 08:18, 2 April 2024
- Communicated by [[Gnaiger Erich]] (2018-10-15) last update 2022-07-10 {{#ask:[[Additional label::Protonmotive force]]7 KB (1,194 words) - 21:50, 10 July 2022
- {{#ask:[[Additional label::BEC 2020.2]] {{Template:Cited by Lane 2022 Transformer}}89 KB (12,074 words) - 17:54, 6 May 2024